支付方对基因疗法的看法。 - Suppr | 超能文献

相似文献

1

The payers' perspective on gene therapies.支付方对基因疗法的看法。

Nat Biotechnol. 2015 Sep;33(9):902-4. doi: 10.1038/nbt.3332.

2

The business case for cell and gene therapies.细胞与基因疗法的商业案例。

Nat Biotechnol. 2014 Dec;32(12):1192-3. doi: 10.1038/nbt.3084.

3

Will rising prices and budget constraints prevent patients from accessing novel gene therapies?

Gene Ther. 2017 Sep;24(9):542-543. doi: 10.1038/gt.2017.66. Epub 2017 Sep 7.

4

Delivering advanced therapies: the big pharma approach.提供先进疗法：大型制药公司的方法。

Gene Ther. 2017 Sep;24(9):593-598. doi: 10.1038/gt.2017.65. Epub 2017 Jul 24.

5

Promising gene therapies pose million-dollar conundrum.前景光明的基因疗法带来了百万美元的难题。

Nature. 2016 Jun 16;534(7607):305-6. doi: 10.1038/534305a.

6

The path to successful commercialization of cell and gene therapies: empowering patient advocates.细胞和基因疗法成功商业化之路：赋予患者权益倡导者力量。

Cytotherapy. 2017 Feb;19(2):293-298. doi: 10.1016/j.jcyt.2016.10.017. Epub 2016 Dec 9.

7

Commercialization of gene therapy drugs.基因治疗药物的商业化。

J Coll Physicians Surg Pak. 2013 Dec;23(12):908.

8

Developing a balanced business model for gene therapy.

Hum Gene Ther. 2011 Jun;22(6):645-6. doi: 10.1089/hum.2011.2504. Epub 2011 May 17.

9

Gene Therapy Briefs.

Hum Gene Ther Clin Dev. 2015 Dec;26(4):211-5. doi: 10.1089/humc.2015.29005.bfs.

10

It's time for gene therapy to get disruptive!是时候让基因治疗产生颠覆性影响了！

Hum Gene Ther. 2012 Jan;23(1):1-3. doi: 10.1089/hum.2011.2530.

引用本文的文献

1

The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.COVID-19 对细胞和基因治疗行业的影响：干扰、机遇和未来前景。

Drug Discov Today. 2021 Oct;26(10):2269-2281. doi: 10.1016/j.drudis.2021.04.020. Epub 2021 Apr 21.

2

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.高成本一次性治愈性疗法实施基于结果的推广支付的障碍与机遇

Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.

3

Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies.

本文引用的文献

1

Glybera's second act: the curtain rises on the high cost of therapy.Glybera的第二幕：高昂治疗费用的帷幕拉开了。

Mol Ther. 2015 Feb;23(2):217-8. doi: 10.1038/mt.2014.248.

2

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.索磷布韦治疗丙型肝炎患者的成本效益

J Viral Hepat. 2015 Apr;22(4):376-83. doi: 10.1111/jvh.12311. Epub 2014 Sep 15.

3

The special case of gene therapy pricing.基因治疗定价的特殊情况。